ÂÜÀòÂÒÂ×

Andrew Steinsapir has a long history of work experience in the field of gene therapy. Andrew is currently a Director and Gene Therapy Program Lead at Deerfield Management and Acting Chief Technology Officer at Apertura Gene Therapy. Prior to this, they were a Consultant for Dark Horse Consulting Inc. from 2017 to 2021, where they provided strategic and technical consultation for cell and gene therapy companies. From 2014 to 2017, they were a Senior Process Development Associate I and Process Development Associate II at 4D Molecular Therapeutics, where they were part of the team engaged in key IND-enabling process development studies. From 2011 to 2013, they were a Volunteer Research Associate at Schaffer Research Group, where they performed high-throughput protein engineering via directed evolution to produce novel lentiviral and adeno-associated viral vectors for gene therapy applications. Lastly, they were a Student Assistant at Lawrence Berkeley National Laboratory from 2013 to 2014, where they worked on optimization and scale-up of recombinant protein expression, purification, and refold in E. coli.

Andrew Steinsapir has a diverse educational background. Andrew obtained a Diploma from Claremont High School in 2010, followed by a Bachelor of Science in Chemical Engineering from the University of California, Berkeley in 2013. In 2017, they obtained a Lean Six Sigma Green Belt from Purdue University. Andrew is currently pursuing a Master of Business Administration from the University of California, Berkeley, Haas School of Business, which they are expected to complete in 2022.